Clinical Research Directory

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged ≥ 18 years old 4. ECOG performance status ≤ 2 5. Planned to receive FDA approved CAR T-cell therapy for large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, chronic lymphocytic lymphoma, or multiple myeloma including (but not limited to): idecabtagene vicleucel, lisocabtagene maraleucel, ciltacabtagene autoleucel, tisagenlecleucel, brexucabtagene autoleucel, or axicabtagene ciloleucel 6. At least one of the following: 1. Platelet count \<200K 2. High CAR-HEMATOTOX score 7. Organ Function per the following criteria: Plt - \>20K CrCl - \>30 ml/min, (expectation for participants with chronic kidney disease presenting with CrCl \<30 but within 15% of baseline) Bilirubin - \<3.0 (unless diagnosed with Gilbert's, can be to PI discretion) AST and ALT - ≤ 3 x ULN 8. Ability to take oral medication and be willing to adhere to the avatrombopag regimen 9. Agreement to adhere to Lifestyle Considerations throughout study duration Exclusion Criteria: 1. Subjects who are at increased risk for thromboembolism, including patients with platelets \> 400k/ul, previously known genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency) and acquired risk factors (e.g., antiphospholipid syndrome). 2. Pregnancy (urine or blood beta-hcg) or lactation 3. Known allergic reactions to components of the avatrombopag, specifically subjects with anaphylaxis, bleeding, or other severe adverse reactions related to avatrombopag or its components 4. Treatment with another investigational drug within 3 weeks prior to registration. 5. Subjects with acute arterial or venous thromboembolism within the past 6 months 6. Subjects with a history of MDS or AML